Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Holdings Decreased by State Street Corp

State Street Corp decreased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 9.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,728,144 shares of the company’s stock after selling 182,547 shares during the period. State Street Corp’s holdings in Kymera Therapeutics were worth $81,793,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Kymera Therapeutics by 8.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after purchasing an additional 915 shares during the period. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics during the third quarter valued at $61,000. Arizona State Retirement System increased its stake in shares of Kymera Therapeutics by 15.6% during the second quarter. Arizona State Retirement System now owns 12,830 shares of the company’s stock valued at $383,000 after acquiring an additional 1,730 shares during the period. Finally, Handelsbanken Fonder AB increased its holdings in shares of Kymera Therapeutics by 12.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 17,300 shares of the company’s stock valued at $819,000 after purchasing an additional 1,900 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on KYMR. Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. UBS Group dropped their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research report on Monday, November 4th. BTIG Research assumed coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $60.00 target price for the company. Morgan Stanley upped their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Finally, Stephens assumed coverage on shares of Kymera Therapeutics in a research report on Monday, November 18th. They set an “overweight” rating and a $65.00 target price for the company. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $53.88.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $43.06 on Tuesday. The company has a 50 day simple moving average of $46.27 and a 200 day simple moving average of $43.07. Kymera Therapeutics, Inc. has a 1 year low of $22.35 and a 1 year high of $53.27. The firm has a market cap of $2.79 billion, a PE ratio of -18.40 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Kymera Therapeutics’s quarterly revenue was down 20.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.90) earnings per share. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.